Followers | 839 |
Posts | 120506 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
Tuesday, October 10, 2017 1:59:15 PM
If the list you posted is correct, then M710 (the codename of the next FoB in the MYL-MNTA partnership to enter the clinic) is presumably Xolair.
MNTA previously disclosed that M710 was for an autoimmune/inflammation indication, and Xolair fits the bill. Also, like Orencia (M834), Xolair is a drug where the number of FoB players will be few. (I'm not aware of another Xolair-FoB program in development, although there may be one.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM